January 13-17, 2018 – Stop by Booth #109 to learn how our whole-genome amplification systems and our NEW NxSeq®UltraLow DNA Library Kit can help you push the limits of next gen sequencing by dramatically loweringthe DNA input requirements while also generating better next gen sequencing DNA libraries and results!
November 2017 – The past two quarters have seen some top-notch work from the team here at Lucigen. The team members pictured here helped the organization achieve its objectives through their excellent contributions, often during demanding situations.
These employees shared their unique expertise with the company to, among many activities, manage the installation of impressive new equipment investments, advance the organization's infrastructural capabilities, successfully address time-sensitive projects with a focus on the customer, and support their peers on an extraordinary level.
Thank you all for helping to drive Lucigen's efforts to whole new heights this year!
November 16-18, 2017 – Stop by Booth #900 to learn how our whole-genome amplification systems can help you with those limiting DNA samples and how our NxSeq® NGS products, including our NEW NxSeq® UltraLow Library Kit, can help you to generate better next gen sequencing DNA libraries and results!
November 8, 2017 – Next gen sequencing (NGS) is rapidily growing in popularity due to the power of the technology. As its popularity increases, researchers continue to push the limits of current technologies to accommodate challenging samples and applications. In order to access these difficult sample types and applications, multiple steps in the NGS workflow must be optimized including DNA fragment library preparation and PCR amplification. This webinar will look in-depth at library preparation with a special focus on the key steps of adaptor ligation and PCR amplification. We will explore how both maximizing efficiency of adaptor ligation and increasing uniformity of PCR amplification across all DNA library fragments can minimize PCR bias and increase sequencing results quality. Specifically, we will introduce the new NxSeq® UltraLow DNA Library Kit which meets these important requirements, enabling the production of high quality DNA fragment libraries from as little as 50 pg to as much as 75 ng of DNA.
October 17-21, 2017 – Stop by Booth #607 to learn how our (i) NxSeq® NGS products, including our NEW NxSeq® UltraLow Library Kit, can help you to generate better next gen sequencing libraries and results as well as (ii) our whole-genome amplification systems can help you with those limiting DNA samples!
October 5, 2017 – Lucigen Corporation and Illumina Inc. have entered into a License and Knowledge Transfer Agreement (effective September 13, 2017) whereby Lucigen will manufacture and sell the entire Epicentre product portfolio through its worldwide distribution network.
Over the last few months Lucigen has been distributing the entire Epicentre line. This Agreement completes the manufacturing transfer to Lucigen of all Epicentre products. Researchers worldwide can now rely on prompt supply of Epicentre’s high-quality products and continued outstanding technical support from Lucigen.
“We are excited to be able to offer this complete line of genomics products to researchers. A combined Lucigen and Epicentre product portfolio provides a broad set of unique tools that deliver innovation and ease of use to life scientists,” stated Jeff Williams, President of Lucigen.
“This deal is a win-win for all parties, especially customers,” stated Mark Van Oene, Chief Commercial Officer at Illumina. “Consolidating the sole source and manufacturing of the Epicentre products through Lucigen and its distribution partners simplifies transactions for customers, puts the infrastructure in place to support product line development, and ensures excellence in customer and technical support worldwide.”
Lucigen is proud to bring this expanded portfolio of innovative products to Life Science Professionals.
October 3-4, 2017 – Stop by the Lucigen booth at SynBioBeta San Francisco, and learn how we can help you scale your workflow using the highest quality enzymes, cloning products and highest efficiency competent cells available.
September 20, 2017 – Lucigen, a leading provider of molecular biology enzymes and kits, announced the issue of U.S. Patent #9765343 for the pJAZZ® BigEasy® System, which offers the unique ability to stably reproduce large or challenging sequences of DNA. Conventional vector systems often fail to give good results with tough-to-clone DNA sequences from humans, parasites, plants, and other organisms. The pJAZZ system gives researchers the ability to study genes that were previously inaccessible. Many of these genes are related to disease pathways with potential for gene therapy. Other applications include creating novel biological products, such as bio-fuels or high-strength fibers derived from spider silk genes. Lucigen's unique pJAZZ technology is available for licensing. For any inquiries, please email email@example.com.
“We are excited about the potential of this new technology. Providing a tool allowing researchers to do something they could not do before opens the door to new discoveries and possible cures,” said Jeff Williams, President.
September 13, 2017 - RNA was long underrated as simply the cellular messenger of genetic information between DNA and expressed proteins. It’s now clear that RNA molecules play many roles within cells in addition to translation (mRNA), such as translation inhibition (miRNA), bacterial defense (CRISPR gRNA) and as transmission of genetic material for many viruses.
In vitro transcribed RNA is an integral component in many research projects aimed at understanding these important cellular functions and viruses. The speed and scale of RNA production, as well as the ability to incorporate chemically modified nucleotides, support an array of exciting research applications.
July 12, 2017 - Artificial gene synthesis (DNA printing) is a powerful synthetic biology tool allowing fast, error-free assembly of almost any desired DNA sequence. Many modern genomics applications start with gene synthesis, including protein production, antibody library generation and cell engineering. In this webinar we will discuss how you can take control of your workflow and accelerate your research by synthetically building and cloning genes and gene variants on your own benchtop. We’ll learn how the BioXp™ 3200 System assembles your gene of interest in silico, utilizing specific and targeted sequence modifications for more efficient results. We will discover how this versatile genomic workstation creates your gene, automates cloning and advances the DNA through various workflows to streamline and speed genomic discovery.
Key Learning Objectives
June 25-28, 2017, Cambridge, UK - Stop by Booth #6 to learn how our (i) NxSeq® NGS products can help you to generate better next gen sequencing libraries and (ii) competent cells and vectors can assist with difficult clonings or toxic protein expression! Also, we’re doing a Satellite Session presentation titled, “Overcoming the Challenges of Illumina DNA Library Prep.” Our speaker would be thrilled to have you in the audience!
|From left to right: Wilbur Ross, U.S. Secretary of Commerce; Glaselyn Miller, |
Lucigen Director of Global Sales and Distribution; Jeffrey Williams, Lucigen
P resident;Kenneth Hyatt, Acting U.S. Under Secretary for International Trade
“The ‘E’ Awards Committee was very impressed with Lucigen’s tremendous export growth over the past four years. The company’s flexible international sales model tailored to individual markets was also particularly notable,” said Secretary of Commerce Wilbur Ross.
“We are extremely honored to receive these distinct recognitions. Lucigen is committed to export expansion, and we have made significant investments to support these efforts,” said Jeff Williams, President. Lucigen recognized the opportunity to export early in its history, appointing its first group of distributors in 2002. But, it was not until after Lucigen’s participation in the Wisconsin Exportech™ program in 2013 that a focused effort was placed on exports.
The company has recognized the potential to expand its presence to more complex markets like India and China. “In 2014, Lucigen accelerated growth of international sales by taking part in various trade missions sponsored by the Wisconsin Economic Development Corporation (WEDC) and by leveraging the resources available from the U.S. Department of Commerce, Commercial Services,” recounts Glaselyn Miller, Director of Global Sales and Distribution. Today, Lucigen is able to bring Wisconsin-made products to scientists around the globe, directly or through its network of 50 distributors.
|From left to right: Ray Bandziulis, Vice President, Quality Assurance |
& Regulatory Affairs; Gary Palmer, Distribution Manager; and
Wisconsin Governor Scott Walker.
“More Wisconsin businesses are recognizing the importance of being part of the global economy, and I commend this year’s award winners for their role in the state’s overall exporting success,” Governor Scott Walker said. “This year’s winners – like many Wisconsin companies – realize they need to look beyond the U.S. borders to capitalize on the demographic shifts that are creating new demands internationally for products and services,” noted WEDC secretary and CEO Mark R. Hogan.
Lucigen’s exports, in 2016, were up 34 percent over the previous year. Within the last year, the company has added 10 distributors to its global network, helping push its exports to an all-time high. Prior to 2016, in addition to a membership with ExporTech, Lucigen participated in two trade missions, to India and China, through WEDC. In the future, Lucigen plans to grow its presence in emerging markets such as Latin America and the Middle East.
“We are extremely honored to receive this distinct recognition. Lucigen is proud to be a Wisconsin-based company committed to export expansion, and we want to thank WEDC, MITA, and ExporTech for their support of our efforts,” said Lucigen President Jeff Williams. “Our dedicated employees and strong distributor partnerships have been integral to achievements like this. We’re excited to continue providing accessible, affordable products worldwide – while growing jobs right here in Wisconsin.”
May 2017 - All of us here at Lucigen are excited to recognize four top-performing employees from this last quarter. Karen Kleman, Buck Webb, Steve Hildebrandt, and Sveta Jasinovica proved that delivering projects ahead of schedule, accommodating customers’ changing needs, and going above and beyond all make them stellar employees who do outstanding work.
Thank you four for your excellence and dedication to Lucigen! #weheartscience
May 10-11, 2017 - Attend the LabRoots Genetics & Genomics free virtual conference! Stop by our booth to chat live with us about solutions for NGS library prep, whole genome amplification from limiting samples, difficult cloning and high efficiency library preparation.
May 10, 2017 - E. coli is often chosen as a host for recombinant protein expression because it’s easily manipulated and produces high yields of recombinant protein. Obtaining sufficient recombinant protein is often one early step in a long research project, so progressing quickly from cloned or synthesized cDNA to soluble, active protein is essential. Whether your lab is expressing a single target or multiple targets in a high-throughput screen, common challenges such as toxicity, low solubility or expression levels, and inefficient fusion tag cleavage can slow or stop progress. In this webinar we will discuss scalable solutions to speed and simplify protein expression at every step, including cloning, expression, and testing of protein yield and solubility. We will discuss novel fusion tags that enhance solubility, and tips and tricks for efficient fusion tag cleavage. We will also introduce methods to express difficult targets, and present case studies illustrating toxic or insoluble protein production from cloning through functional characterization.
Key Learning Objectives:
May 1-5, 2017 - Stop by booth #409 and learn how to increase your yield of soluble recombinant protein from E. coli, and how to improve your phage display libraries with the highest quality, highest efficiency phage display competent cells available.
April 4, 2017 - Lucigen Corporation announces it has signed a global agreement with Illumina, Inc. for Lucigen to be the sole distributor of Epicentre Technologies’ genomics kits, enzymes and ancillary reagents. Products covered by this new agreement are in addition to the select Epicentre products that were licensed and transferred to Lucigen for manufacture and distribution in December 2016.
Effective immediately, Lucigen Corporation will distribute the complete Epicentre product portfolio.
Epicentre Technologies, known for its genomics and transcriptomics products for gene expression, cloning, and in vitro transcription, was acquired by Illumina in 2011.
Lucigen manufactures and supplies products that advance research in the fields of synthetic biology, next generation sequencing, genetic amplification, and protein expression.
“We are excited for Lucigen to expand its Epicentre product offerings,” said Mark Van Oene, Chief Commercial Officer for Illumina. “Lucigen has been a tremendous partner to Illumina and this agreement will continue to benefit scientists by delivering a full portfolio of great products.”
“Illumina shares our commitment to serve scientists worldwide with high quality products that enable scientific breakthroughs. Providing a single-vendor solution gives life science professionals easy and seamless access to these products. The incorporation of products from the Epicentre portfolio, combined with Lucigen’s portfolio of genomics products, will help scientists accelerate and simplify their research,” stated Ralph Kauten, CEO of Lucigen.
April 1- 5, 2017 - Stop by Booth# 2263 to learn how NxSeq® NGS products can help you to generate better next gen sequencing libraries!
February 2017 - At a trade show last year, a new customer made sure to stop by the Lucigen booth to personally thank our team for the support we had provided on a large OEM project in synthetic biology. The organization was extremely complimentary of our employees’ highly responsive troubleshooting capabilities and flexible customer service. Additionally, the Lucigen team made sure to deliver high-quality product on time, time after time, resulting in a strong relationship that continues today. We wouldn’t be able to do the work we do here at Lucigen, and grow our business while doing it, without such dedicated employees! A big THANK YOU to our wonderful employees for outstanding collaboration with a new partner. #WeloveScience
February 2017 - Lucigen receives $323k SBIR grant from National Institutes of Mental Health (NIMH), “Tools for Exceptional Overexpression of Membrane Proteins in Mammalian Cells”. The project seeks to overcome challenges that limit scientists’ ability to study human membrane proteins such as G-protein coupled receptors (GPCRs). These proteins control myriad processes in the human body, and are the targets of many drugs in the marketplace. This grant supports the development of tools to increase the yield of functional GPCRs from mammalian cell culture, and to speed the processes to determine the 3-dimensional structures of these proteins. These tools may impact human health by enabling development of improved drugs to better target specific cellular signaling pathways.
January 9-12, 2017 - Representatives of Lucigen used the meeting to introduce and renew contacts with a number of partners and potential collaborators. One-on-one meetings were held with a number of companies, mostly those interested in Lucigen's NGS products and technologies.
January 2017 - This year, in addition to his primary duties as Lucigen’s vice president of operations and diagnostics, Mr. Jay Schiestle will join a team-taught graduate course at the University of Wisconsin-Madison. As a part-time adjunct professor, Mr. Schiestle will supplement teachings by the course’s lead instructor, Dr. Ed Elder, with his own expertise in biomanufacturing and operations. Mr. Schiestle will collaborate with students of the Masters in Biotechnology program at UW’s School of Medicine and Public Health to provide them with “real-life” experience in the larger biotechnology industry.
In the program, Mr. Schiestle will serve on a team with Dr. Elder and Mr. Dave Bormett, Executive Director of QA at Arrowhead Pharmaceuticals. As an employer of UW graduates, Lucigen is proud to support the university in developing students for future careers in the biotechnology marketplace—locally and beyond.
January 14-18, 2017 - Stop by booth #408 to enter a drawing to win a $250 Amazon Gift Card. While you’re there, we can discuss how we can help you overcome some of the challenges you’re facing in the laboratory. For example, we can discuss how to construct Illumina-compatible DNA fragment libraries that significantly improve the diversity of your libraries and in turn the quality of your NGS data. We can also chat about solutions for successfully amplifying entire genomes from single cells or 1 fg of gDNA with minimal bias. So stop by and see how we can help you.
December 2016 - Over the past month, Lucigen joined the Madison Metropolitan School District (MMSD) for two career-oriented events. Having worked with students at Memorial High School to develop their interest in healthcare, Jay Schiestle and Marie Uphoff—VP of Operations & Diagnostics and Project Manager, respectively—recently brought Lucigen’s team to a recruitment night for incoming high school first-years. They were joined by Tony Rockweiler, R&D Scientist; Eric Steinmetz, R&D Principal Scientist; and Michele Auldridge, R&D Senior Scientist. At this event, the Lucigen team talked with interested MMSD parents and 8th graders about the Health Care Career Pathway program and potential careers in the life-science industry. 8th graders who apply will have their application reviewed before joining the program. Memorial plans to include about 100 students in its Pathway program for the 2017-2018 school year.
At the second event, Glaselyn Miller, Director of Global Sales & Distribution at Lucigen, presented to students for the School Makes a Difference (SMAD) program. As part of the SMAD program, sponsored by MMSD’s Office of Personalized Pathways and the Greater Madison Chamber of Commerce, students engage with presenters to learn about various careers and career journeys. Glaselyn shared her occupational experiences and current role to help inspire Madison’s high school students to consider professions in the biotech industry, sales, and international business. Lucigen is excited to support both programs in helping MMSD students identify and achieve their biotech vocational goals.
November 29, 2016 - With this agreement, effective January 1, 2017, select Epicentre products will be manufactured and sold exclusively by Lucigen Corporation directly to customers and through its distribution network worldwide. Epicentre Technologies, known for its genomics and transcriptomics products for gene expression, cloning, and in vitro transcription, was acquired by Illumina in 2011, and continues to operate as a wholly owned subsidiary of Illumina in Madison, Wisconsin. This select group of products for transposomics, microarray analysis, and transcriptomics complements Lucigen’s portfolio of tools for use in synthetic biology, next generation sequencing, genetic amplification, and protein expression
The incorporation of products from the Epicentre portfolio broadens Lucigen’s portfolio of genomics tools that accelerate and simplify life science research. Illumina’s agreement with Lucigen reflects good cooperation between the companies in order to continue the delivery and service of these high quality products to life science researchers. “We are excited to expand and enrich our product offering to serve scientists worldwide with unique tools that will deliver innovative and meaningful breakthroughs in life sciences” stated Ralph Kauten, CEO of Lucigen.
November 16, 2016 - Lucigen was recently honored at the Wisconsin Early Stage Symposium, together with other local companies that have been awarded a Small Business Innovation Research grant in the last year. Principal Scientist, Eric Steinmetz, from Lucigen received an SBIR grant for his research on Tools for Exceptional Overexpression of Membrane Proteins in Mammalian Cells. The aims of this grant are to enable improved expression of membrane proteins, which are key subjects of ongoing biomedical research and targets of many pharmaceuticals. We are honored to receive this recognition, and excited for the research opportunity it provides Lucigen to improve outcomes in the field of producing challenging proteins for biomedical research.
November 10-12, 2016 - Visit us at booth #726 to discuss how we can help you overcome some the challenges you’re facing in the laboratory. For example, we can discuss solutions for successfully amplifying entire genomes from single cells or 1 fg of gDNA with minimal bias or constructing Illumina-compatible DNA fragment libraries that significantly improve the diversity of your libraries and in turn the quality of your NGS data.
October 2016 - The Korea Biotechnology Industry Organization and Seoul Metropolitan Government have invited Lucigen, among other US companies, to attend the “Seoul Bio-Medical Conference 2016,” which will be held in the South Korean capital this Friday, October 21st. Ms. Julie Kramer, Director of Marketing and Mr. Mark Maffitt, Director of R&D, will represent Lucigen at this event. We look forward to fostering new relationships with our South Korean biotech peers as we pursue solutions to our industry’s scientific endeavors.
October 21, 2016 - Members of Lucigen’s marketing, sales, R&D, and quality teams collaborated with the Wisconsin Science Festival to explore the value of science to our world. Taking place at the Discovery Building in downtown Madison, the annual event celebrated its sixth outing. As a company and community partner, we were glad to be able to celebrate our love for science with community members and to teach students about the importance of various scientific disciplines.
October 18-22, 2016 - Visit us at booth #1523 to discuss how we can help you overcome some of the challenges you’re facing in the lab. For instance, successfully amplifying gDNA from single to a few cells with minimal bias or constructing Illumina-compatible DNA fragment libraries that improve the quality of your NGS data.
October 16-19, 2016 - Visit us at Booth #5 with Douglas Instruments! Learn about our fast, one-step amplification kit for RNA or DNA targets using LAMP isothermal amplification and our upcoming LAMP DNA Master Mixes- compatible with fluorescent RT-PCR instruments and the Douglas AmpliFire!
October 5-7, 2016 - Be sure to stop by the Lucigen table to hear the latest on how our Illumina-compatible NGS library prep kits can help you decrease costs, improve data quality and enable library construction with DNA samples you'd normally reject.
October 4-6, 2016 - Stop by the Lucigen booth to learn about our cloning system for large operons and biosynthetic pathways, and how our high-efficiency competent cells improve your cloning projects – even high-throughput cloning!
Visit Lucigen's poster Complex Genetic Circuitry in pJAZZ® Linear Vector.
Abstract: A new mammalian expression vector shows unprecedented ability to express large operons, tandemly-repeated protein subunits, and multi-protein complexes in bacterial and mammalian cells. Expression is based on the unique linear pJAZZ vector, which enables stable cloning of difficult or repetitive sequences that cannot be maintained in circular plasmids. The pJAZZ vector can accommodate inserts of up to 40 kb, allowing expression of multiple genes and multi-protein complexes. For example, it was the only vector that enabled cloning of four direct repeats of the inositol 1,4,5-triphosphate (IP3) receptor gene for production of a functional 1000-kDa (1 MegaDa) Ca++ channel protein in mammalian cells.
We have also evaluated pJAZZ as a vector to support isoprene production. Expression of a 9.3 kb E. coli isoprene operon cloned into pJAZZ was ~10X higher than that achieved by co-expression of multiple independent circular plasmids. A blue light-inducible system has been used to permit on-demand gene expression in mammalian cells, with spatial and temporal resolution that cannot be achieved with classical small molecule-based induction systems.
October 3-4, 2016 - Visit us at Booth #12 to learn how to get more data from your NGS fragment libraries and how to get whole genome amplification without using random primers.
We at Lucigen are very proud to announce that our CEO, Ralph Kauten, was honored with BioForward’s BioHealth Business Achievement Award today. It is a special privilege to be honored by an organization local to the area in which we work, especially one like BioForward, which is dedicated to supporting and growing Wisconsin’s bio-health industry. Having served as co-founder and leader at a number of biotechnology companies—Promega Corporation, PanVera Corporation, Mirus Corporation, and Lucigen among them—Ralph continues to foster innovation and advocate for biotechnology in our local community and beyond.
Congratulations, Ralph! All of us here at Lucigen continue to be fortunate enough to learn from you and work with you to provide products and services that change people’s lives.
June 16-20, 2016 - Stop by Booth #2143 to learn how our next gen sequencing kits can improve your microbial sequencing. Hint: only 75 ng DNA input with no PCR amp required for DNA fragment libraries!
April 25-29, 2016 - Stop by Booth #434 to learn about our superior transformation efficiency competent cells for phage display and innovative screening kits for expressing soluble protein. Visit us to discuss how Lucigen products can improve your results and workflow.
April 16-20, 2016 - Stop by Booth #355 to learn about our Next gen sequencing DNA library kits that require only 75 ng of DNA input and NO-PCR amp step! Visit us to discuss how the kit can improve your DNA sequencing results and workflow.
March 6-11, 2016 - Stop by Booth #204 to learn the latest about the ClariLight CLIA-Waivable MDx Platform, including 30 minutes from sample to result. Also learn about generating bigger data from your next gen sequencing DNA fragment libraries.
Attend our talk: Reimagining the Future for a CLIA-Waivable Point-of-Care Molecular Diagnostic Platform.
LucigenDx will describe a new platform designed to bring molecular diagnostics to the point-of-care. The platform consists of a test cartridge and a compact instrument designed for CLIA-waiver. Sample extraction, amplification and detection are performed by the isothermal amplification platform.
Thursday, March 10, 2016
Point-of-Care Diagnostics Symposium
February 20-23, 2016 - Stop by to learn about our low input NGS library prep kits -- get more and better NGS data while also saving time and money using the NxSeq® AmpFREE Low DNA Input Kit.
January 8-13, 2016 - Stop by booth 420 to learn how to get more and better NGS data while also saving time and money using the NxSeq® AmpFREE Low DNA Input Kit. Or we can discuss other ways we can help you with your CRISPR, phage display, cloning and PCR research needs.
Also see our posters:
P0229: Genome Technology: Large Insert Libraries
BAC Sudoku Sequencing Strategy for in silico Screening of Large-Insert Soil Metagenomic Libraries
P0773: Genome Mapping, Tagging & Characterization: Maize, Sorghum, Millet, Sugar Cane, and related Assembly, Closing and Finishing of the Sorghum Bicolor Bicolor BTx623A1 Cytoplasmic Cytoplasmic-Male Sterility (CMS) Mitochondrial Genome: Identification of a NOVEL Fusion Orfs in the Mitochondrial Genome of Cytoplasmic Male Sterile Sorghum BIC
December 15, 2015 - December 2015, here at Lucigen, marks the second anniversary of our certification to the ISO13485 quality management standard for medical devices. Certifications are earned through successful completion of audits by authorized, third-party registrars. We recently completed our second annual audit this fall, and continuing our track record of strong performance, with no serious problems or issues raised by the registrar, BSI, Inc. The certifications are granted for three years, and companies are monitored with annual surveillance audits looking at how well their systems perform and how they conform to the ISO13485 standard. Lucigen will re-certify to the standard in the fall of 2016. For more information on ISO and the 13485 certification see the article “Understanding ISO 13485,” in Quality Magazine.
November 12, 2015 - This past week, Lucigen’s Quality System Manager Lynne Sheets stopped by MATC to talk to current students of their biotech program. She touched on the value of a the career in biotech program, and the intersections of a career in quality assurance with an MATC biotech education, and the benefits of working for a growing company like Lucigen. On finding that “perfect” job, Lynne had this to say: “Be open to new challenges. They may lead you down unexpected and rewarding paths.” Lucigen is proud and excited to continue working with educators to grow talent right here in Wisconsin!
November 5-9, 2015 - Visit Lucigen at Booth #628 to learn about LucigenDx ClariLight™ and NxSeq® low input fragment library kit.
Attend our workshop: "Reimagining the Future of Point-of-Care Molecular Diagnostics for Infectious Disease"
Wednesday, November 4 | 11 AM | Room 12b
LucigenDx will describe a new platform designed to bring molecular diagnostics to point-of-care. The platform consists of a test cartridge and a compact instrument designed for CLIA-waiver. Sample prep, amplification and detection are performed by the isothermal amplification platform with no mixing or measuring. A clinical trial is planned for 2016.
Also see our poster:
PCR-Free, Low Input Fragment Library Kit (PDF)
Scott Monsma, Marie Uphoff, Svetlana Jasinovica, Erin Ferguson, David Mead, and Mike Lodes
October 6-10, 2015 - Visit Lucigen at Booth #2119 to learn how NxSeq helps improve complex NGS assemblies. See our poster:
Mate pair libraries constructed from FFPE samples
David Mead, David Smith, Scott Monsma, Marie Uphoff, and Michael Lodes
Middleton, Wis. (October 2, 2015) – Lucigen Corp announced today that it has successfully completed Illumina CSPro™ certification for next generation sequencing (NGS), gaining entry to an elite group of Illumina genomics service providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.
Illumina CSPro is the collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes.
Angela Ryan, Director of Marketing at Lucigen, states, “Receiving CSPro Certification confirms Lucigen’s commitment to the highest quality consultative NGS service. We offer services from closing and finishing small genomes to improving complex genome assemblies providing larger N50 values. Our processes help resolve structural variants, haplotypes, sub-genomes and other long range contextual information. This certification will allow our highly trained staff to address the most complex NGS challenges in a helpful, collaborative way.”
"Illumina CSPro recognizes organizations that provide customers with industry-leading data quality and service in genetic analysis," said Karen Possemato, Illumina's Sr. Director of Corporate Marketing. "Lucigen is now a Certified Service Provider throughout the world, able to provide NGS services using Illumina technology. Now that Lucigen is a global CSPro partner, we are excited to work with them to make it easier for scientists to access the power of Illumina's genetic analysis technologies."
August 2015 – David Mead, PhD, CSO & Founder, will be giving a talk on "Functional Metagenomics of Soil Microbial Secondary Metabolite Pathways".
Functional Metagenomics for Cloning and Expression of Novel Soil Microbial Secondary Metabolite Pathways
David A. Mead, Scott Monsma, Xing-Cong Li, Blaine A. Pfeifer, Jinglie Zhou, Scott Santos and Mark R. Liles
Middleton, Wis. (July 1, 2015) – Lucigen Corporation was recently awarded a Phase II grant, entitled “Mini Chromosome and Fluorescent Proteins for Expression of Protein Complexes,” to continue work on an exclusive DNA cloning vector for the rapidly growing protein expression market. Ron Godiska, a Ph.D. senior scientist with Lucigen, will be leading the research for this new grant. According to Dr. Godiska, “many cloning kits on the market are ineffective due to unwanted activity of the cloned recombinant gene, which leads to rearrangements or deletions in the cloned DNA sequence.” Dr. Godiska was on the original team that developed Lucigen’s unique BigEasy® vector system to combat errors in gene cloning.
Within this system is the pJAZZ® DNA cloning vector, which is commercialized exclusively by the Middleton-based company. As the only linear vector on the market, the pJAZZ® vector is the most powerful tool for cloning DNA today. Because it is not a conventional circular vector, it can successfully clone particularly difficult genes or clone multiple genes at once.
As part of the grant, the Lucigen R&D team has been applying the pJAZZ® vector’s unique cloning abilities to mammalian cells. Its features make it a highly relevant tool for human diseases.
MarketsandMarkets, a top global firm for market research reports, notes that the protein expression market is expected to hit almost $1.4 billion by 2018, with growth at a CAGR of 8.83%.
Within this protein expression market, according to M&M, “the expression vectors market is expected to reach $317.1 million by 2020 from $242.7 million in 2015.”With this grant-funded focus, Lucigen can now expand from the bacterial protein expression market into other disease-relevant areas.
May 30 – June 2nd, 2015 Booth #117.
Lucigen presents on:
NxSeq® Mate Pair Technology: visit Lucigen to see how you can close and finish your microbial genome using an existing fragment library and a single mate pair library, sequenced on your short read sequencer.
May 11-12, 2015 Lucigen presents, "Closing and Finishing Genomes with Long Mate Pair NGS Libraries" on May 12, 2015, 11:45 AM.
Abstract: Repetitive DNA elements are abundant in most species, creating technical challenges for the accurate de novo assembly of genomes. New methods that generate user defined mate pair (MP) libraries up to 100 kb have been developed and validated, with important consequences for assembling and closing repeat rich, complex genomes from fungi, mitochondria, chloroplasts, plants and animals. Bacterial genomes can be automatically closed and finished with a 20 kb MP library and SPAdes genome assembler software. We also report on improved scaffolding of human, maize, switchgrass, and sorghum mitochondrial genomes with 20-100 kb mate pair libraries. The ability to construct and sequence mate pair libraries up to 100 kb simplifies the accurate closing and finishing of complex genomes economically.
Middleton, Wis. (May 5, 2015) – Lucigen Corporation announced today that it has signed an exclusive distributorship agreement with Sigma-Aldrich Corporation’s (NASDAQ: SIAL) India subsidiary, Sigma-Aldrich Chemicals Private Ltd., to expand commercialization of life science reagents in India.
The synergy between the two companies will provide researchers in India an enhanced customer experience, strong technical support, and easy access to Lucigen’s broad portfolio of products and services.
Ralph Kauten, CEO & Chairman of the Board for Lucigen Corporation, noted, “Sigma-Aldrich’s market knowledge and logistics operations in India will enable Lucigen to reach scientists in all corners of India, providing them with leading technologies in Next Generation Sequencing, Cloning and Protein Expression systems.”
The distributorship will also address the need to increase availability of easy-to-use products in one of the fastest growing life science research markets. “Growth in the overall life science research tools market will be fueled by demand in the so-called BRIC nations — Brazil, Russia, India, and China — which are expected to grow 13 percent CAGR,” according to a report by DeciBio, a life sciences market research firm.
Through the diversified portfolios of large firms like Sigma-Aldrich, the report specifically notes, market opportunities have already led to high growth. The Indian market, in particular, is expected to grow anywhere from 10 to 15 percent in support of the $45.8 billion global projection for 2016.
This agreement is a direct result of a program between the Wisconsin Economic Development Corporation (WEDC) and the Council of Great Lakes Governors, which enabled Lucigen to participate in a trade delegation that visited India in April 2014.
May 4-8th, 2015 - Booth #326
"New Tools for Protein Solubility" David Mead, CSO & Founder on May 4th, 12:05 PM | Expression Stream
Learn more about our Expresso Solubility & Expression Screening System & Service
Posters in Session B:
Linear Vector for Bacterial or Mammalian Expression of Repetitive Genes or Operons
Solubility and Expression Screening Panel for Difficult Proteins
March 25-28th, 2015 - Lucigen's Yogesh Chander, PhD, is a keynote speaker talking on development of point-of-care ebola diagnostics.
Lucigen presents a poster:
"Long Span Mate Pairs Approaching 100 kb for Closing Genomes: Closing and Finishing the Mitochondrial and Chloroplast Genomes of Sorghum Male-sterile A1 Cytoplasm"
Abstract: Long repetitive DNA sequences are abundant in most species, which creates technical challenges for the de novo assembly of even small genomes using short read next generation sequencing (NGS) methods. The incorporation of long span mate pair reads dramatically improves the success of de novo assembly and the discovery of structural variants by resolving repeat elements and ordering contigs. A new NGS library method that generates user defined mate pairs (MP) up to 100 kb has been developed. A fosmid based technology for 30-50 kb MP libraries has been used to close multiple repeat rich, complex genomes. A clone free version has been developed for 2-8 kb, 10-20 kb and beyond using bead-based and gel-based methods. A unique barcoding strategy is used to distinguish true mate pairs from false chimeric junctions, dramatically reducing the fraction of misassembled contigs. We report the closing and finishing of four bacterial genomes, and closing several plant genomes, including Miscanthus sinensis and the CMS sorghum mitochondrial and chloroplast genomes. Download PDF
February 19th, 2015 - Watch live our GenomeWeb webinar on "Finishing Genomes with Long Span NGS Reads" and enter to win free NxSeq Kit!This online seminar will describe new technology capable of generating mate-pair sequencing reads up to 50 kb in length, enabling de novo genome assembly, closure, and finishing on the Illumina or Ion Torrent next-generation sequencing platforms. Register
January 19-23rd, 2015 -Lucigen has a sponsored talk in Pipeline 4: Expression & Production: Engineering Genes, Vectors, Constructs and Clones
"New Tools in Protein Expression" David Mead, CSO & Founder on January 20th, 9:35 AM
Learn more about our Expresso Solubility & Expression Screening System & Service
January 10-14th, 2015 - In addition to having a booth, Lucigen will host a corporate workshop entitled:
"Closing and Finishing Genomes and BACs with Long Span NGS Reads"
January 13, at 1:30 PM in Pacific Salon 1. Detailed schedule below:
>> Attend the workshop for opportunity to win an iPad Mini! Visit us at Booth #105.
Nov. 12, 2014 - Lucigen hosted a corporate workshop, entitled: "A New Rapid, Point-of-Care Molecular Diagnostics Platform for Ebola and Other Infectious Diseases". Our new ClariLight™ platform instrument for point of care diagnostics was unveiled, with a discussion of the workflow and target applications . In addition, a summary of our progress towards a field-deployable Ebola diagnostic assay was presented.
See us at booth # 1122. To request in-person meetings with Lucigen, please email firstname.lastname@example.org.
October 29, 2014 – Lucigen announced today that Ralph Kauten has been named CEO of the organization. Mr. Kauten has served as a member of the corporation's Board of Directors for the past ten years and as the Chairman of the board for the past four years. Previously Mr. Kauten has been involved in the start-up and management of the life sciences companies Promega Corporation, PanVera (acquired by Aurora Biosciences) and Mirus Bio (acquired by Roche Pharmaceuticals). Dr. David Mead, who founded Lucigen and has served as CEO from the company's inception in 1998, will continue to be actively involved in the role of Chief Scientific Officer.
"We are very pleased to have Ralph Kauten join us as CEO. His wealth of leadership experience will be invaluable to the company as we grow and evolve as a premier life science company," states Dr. Mead.
August 20, 2014 – The Ion PGM is a fast and cost-effective platform for next generation sequencing applications. The release of the Ion TrueMate™ Library Kit will expand the platform’s capabilities by allowing long mate pair libraries up to 8 kb to be run on the PGM. Mate pair libraries are critical for de novo genome assembly, chromosomal rearrangement studies, and finishing genomes. Traditional fragment libraries produce large quantities of data but result in sequence gaps, misassembled contigs, and collapsed repeats due to short read lengths. Combining mate pair libraries with fragment libraries has been proven to achieve more accurate genome assemblies.
Developed at Lucigen using their NxSeq® mate pair technology, the Ion TrueMate Library Kit includes multiple innovations that enable high fidelity mate pair libraries without paired end sequencing on the PGM platform. The protocol and reagents have been optimized to eliminate chimera formation, with the inclusion of patent-pending ChimeraCode™ sequences allowing confirmation of actual mate pairs via bioinformatics. The TrueMate libraries demonstrate >90% efficiency of real mate pairs, compared to 30% or less with other platforms. Lucigen’s new Accura™ high fidelity polymerase is also incorporated into the new product.
“Existing mate pair libraries contain a high percentage of chimeras that result in misassembled genomes. The mate pairs that are obtained from the TrueMate libraries achieve >90% efficiency, and when combined with Ion Fragment libraries, have shown tremendous promise for closing genomes, finishing BAC sequences, and obtaining accurate scaffold assemblies,” states Lucigen CEO and Founder Dr. David Mead.
The TrueMate Library Kit will be sold for the PGM platform exclusively through Thermo Fisher, while Lucigen will perform library creation and sequencing services for customers globally.
The release of the Ion TrueMate library kit is the first of multiple mate pair kits in development by Lucigen. Future products will include the ability to create longer mate pairs of 20 kb or higher and the application of whole transcriptome sequencing via Full Length RNASeq protocols.
For research use only. Not for use in diagnostic procedures.
August 2014 – Genotypic Technology and Lucigen Corporation are partnering to present a newly developed long mate pair library prep system that achieves >90% mate pair efficiency, featuring the incorporation of Chimera Code™ sequences to distinguish true mate pairs from false junctions. Genotypic is hosting a Hands-on Workshop on NGS Applications at their Bangalore Centre on September 12-15, 2014. At this workshop, Lucigen NxSeq® long mate pair library data from multiple organisms and BACs will be presented, demonstrating accurate de novo assembly and closing of genomes. Use of NxSeq with Ion Torrent's system enables mate pair reads without the need for paired end sequencing, permitting economical sequence assembly of BAC clones and small genomes, while NxSeq libraries for the Illumina platform allow for long range paired end sequencing up to 8 kb and accurate assembly of large genomes.
This marks the first collaboration between Lucigen and a genomics service provider (Genotypic) in India to build awareness of its NxSeq Technology. Lucigen's highly efficient DNA library prep kits for next gen sequencing and a truly innovative 40kb mate pair cloning kit for whole genome sequencing will be presented at the workshop of NGS applications organized by Genotypic.
To register visit: http://genotypic.co.in/Genotypic-Specials/34/-NGS-Workshop-2014-.aspx
July 17, 2014 – Lucigen has entered phase two of a five-year, $1.7 million, Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to develop a nucleic acid test for three types of viral hemorrhagic fever: Ebola, Lassa, and Marburg. Read More [PDF] >
June 23-26, 2014 – Lucigen will feature information about our point-of-care diagnostic platform at BIO International. Here’s how to learn more:
You can request in-person meetings with Lucigen by emailing email@example.com or using the BIO International partnering forum platform.
Want to learn more about Lucigen's diagnostics solutions? Visit www.lucigendx.com.
May 12-13, 2014
WORKSHOP | Tuesday, May 13 11:10-11:40, Stream 1
High Efficiency Long Insert Mate-Pair Library Preparation for NGS Platforms Lucigen will present a newly developed mate pair library prep system that achieves >90% mate pair efficiency, featuring the incorporation of Chimera Codes™ to distinguish true mate pairs from false junctions. NxSeq™ NGS library data from multiple organisms and BACs will be presented, demonstrating accurate de novo assembly and closing of genomes. Comparable mate pair libraries created from Illumina prep kits yielded <5% true mate pair data. Use of NxSeq with Ion Torrent's system enables mate pair reads without the need for paired end sequencing, permitting economical sequence assembly of BAC clones and small genomes, while NxMate libraries for the Illumina platform allow for long range paired end sequencing and assembly of large genomes
May 5-9, 2014
WORKSHOP | Tuesday May 6, 2014 3:05 PM
New Tools for Difficult Expression Problems: New Solubility Partners and Endotoxin Free DNA and Protein, Lucigen will present a suite of new solubility fusion partners within a robust enzyme-free cloning platform, including a novel fluorescent protein that provides an instant visual report of the amount of soluble, active protein. In addition, attendees will learn about novel competent E. coli cells lacking lipopolysaccharide (LPS) for endotoxin-free protein and DNA production.
Eliminating Endotoxin at the Source: Modified Lipopolysaccharide Competent Cells for Low-Endotoxin Protein and Plasmid Production Eric Steinmetz 1, Uwe Mamat2, Ronald W. Woodard3, Kathleen Wilke2, Chad Souvignier4, David Mead 1, Chelsea Kovacich 1, Curtis Knox 1 1: Lucigen Corporation, Middleton, WI; 2: Research Center Borstel, Borstel, Germany; 3: University of Michigan, Ann Arbor, MI; 4: Research Corporation Technologies, Tucson, AZ
Novel Solubility Fusion Partners: High Throughput Soluble Protein Production System Saurabh Sen, Eric Steinmetz, Sally Floyd, David Mead and Mark Maffitt Lucigen Corporation, Middleton, WI 53562 USA
February 12-15, 2014
True Mate Pair Library Technology Michael J. Lodes1 , Svetlana Jasinovica1, Erin Ferguson1 , Scott Monsma1 , Si Lok3, Amy Tong3, Tim Durfee2, Matthew Keyser2, Tom Schwei2 and David Mead1 1 Lucigen Corporation, 2905 Parmenter Street, Middleton, WI 53562, USA 2 DNASTAR, Inc. 3801 Regent Street Madison, WI 53705 USA;3 Genome Research Center, The University of Hong Kong
January 30, 2014 – Lucigen's efforts to develop a new point of care molecular diagnostics platform are chronicled by reporter Jeff Engel of Xconomy.com: Lucigen Takes On Diagnostic Giants With On-the-Spot Pathogen Tests »
Jan. 11-15, 2014
Workshop: True Mate Pair NGS libraries and Applications #2324 Jan. 14th, Tuesday | 1:30-3:40 PM Mate-pair Libraries are critically important tools for scaffolding and closing genomes. Current technologies cannot resolve repeats or segmentally duplicated sequences, which results in large missing segments of eukaryotic genomes and failure to close small prokaryotic genomes. These limitations make it very difficult and expensive to assemble large or small genomes de novo. Lucigen will present a fresh approach to solving some of the challenges associated with constructing large insert mate pair libraries. The efficient construction of large insert libraries >5 kb was not practical until the development of the pNGS fosmid system for 40 kb mate pair libraries by Lucigen. We will introduce a novel clone free technology for constructing 2-50 kb mate pair libraries. Our strategy involves the use of multiple methods to prevent chimera formation, including the incorporation of Chimera Codes™ that allow one to distinguish true mate pairs from false junctions for de novo sequence assembly. Sequence data from 8kb and 20kb E. coli mate-pair libraries confirmed our expected results of 90% assembled reads (114,869 of 126,930) showing consistent alignment across the entire genome. We have used this technology to close the 22 contig draft Thermus aquaticus genome as well as assemble BAC clones efficiently using Illumina and Ion Torrent platforms. We will also highlight DNASTAR Genomics Suite software, which is uniquely suited for use with data generated by sequencing of Lucigen mate-pair libraries to build scaffolds and close genomes.
See our poster:
High Efficiency Long Insert Mate Pair Library Technology Michael J. Lodes, Svetlana Jasinovica, Erin Ferguson, Scott Monsma, Si Lok, Amy Tong, Tim Durfee, Matthew Keyser, Tom Schwei and David Mead Lucigen Corp & DNASTAR Inc.
Dec. 17, 2013 –Lucigen Corporation today announced that the company has received certification from the British Standards Institution-USA (BSI) that its quality system meets the ISO 13485 standard for medical device and diagnostic product development and manufacturing.
In 2012, Lucigen embarked on an effort to develop its novel polymerase technology into a molecular diagnostic platform for the detection of human and animal pathogens. A critical component to this evolution of the company was to enhance its quality and manufacturing capabilities to the level necessary to meet the regulatory requirements for manufacturing of diagnostic devices. BSI, a leading global certification body, has certified Lucigen as meeting all the requirements of the standard, completing a key step in the process towards submitting a diagnostic test to the FDA. Lucigen plans to enter clinical trials in late 2014, with release of its first molecular diagnostic test in 2015.
In addition to future molecular diagnostic products, the company intends to supply reagents to other molecular diagnostic test developers that need novel RNA and DNA polymerases and other necessary components. Obtaining ISO 13485 certification places Lucigen among the elite molecular biology reagent manufacturers globally. A first look at the company’s offerings for partnership was featured at the annual Association for Molecular Pathology (AMP) meeting on November 13, 2013.
“ISO 13485 certification positions Lucigen to make a profound impact on better health by providing innovative diagnostic tests and OEM solutions for medical diagnostics,” states David Mead, Ph.D., Lucigen founder and CEO.
Dec. 1, 2013 – Lucigen Corporation today announced that The Scientist Magazine has named the company’s ClearColi™ Competent Cells as one of the Top 10 Innovations of the year. In the 6th year of the competition, The Scientist’s judges focus on the core meaning of “innovation,” recognizing both small and large companies that have introduced truly revolutionary products for researchers.
This year’s winning products include a mini-microscope that can capture networks of brain neurons firing in real time as mice engage in behaviors, a 3-D imaging platform, and touch-sensitive pads that can be incorporated into robots to prevent damaging collisions. Previous year’s winners have featured breakthrough technologies such as platforms for next generation sequencing (NGS) and pluripotent stem cells. Lucigen’s ClearColi cells have a genetically modified lipopolysaccharide (LPS) that result in a minimal endotoxic response when introduced into animals or human cells as an unintended contaminating byproduct. Many membrane and lipid binding proteins, which are frequently used in drug development are especially challenging to purify free of LPS. By producing proteins using ClearColi cells, researchers can reduce the time, loss of product, and cost associated with endotoxin removal. More importantly, cell-based assays or animal studies can be performed without concern that LPS (endotoxin) contamination could be masking promising results, thereby allowing researchers to accelerate the drug discovery process and obtain the most accurate results possible. The Scientist judges hailed ClearColi as having the potential to “significantly impact the biologics space.”
“The ClearColi cell lines will advance how researchers screen novel proteins, DNA, and small molecules for drug discovery. We are actively developing additional strains for protein expression, plasmid production and protein secretion that will continue to accelerate multiple facets of pharmaceutical research,” states David Mead, Ph.D., Lucigen founder and CEO.
June 2-5, 2013 – David Mead presents:
In the May 22, 2013 issue of Nature, a team of scientists representing a collaborative effort across 28 institutions in 9 countries has published a draft genome assembly of the 20-gigabase genome of the Norway spruce (Picea abies), the first available for any gymnosperm. This large genome features many unique characteristics, including a diverse set of long-terminal repeat transposable elements, numerous long (>10,000 base pairs) introns, gene-like fragments, uncharacterized long non-coding RNAs and short RNAs. Dr. Cheng Cang Wu and his Custom Genomics Services team at Lucigen were instrumental in creating the Spruce pSMART-Fosmid libraries with millions of clones and more than 1,000 fosmid pools that were enabling to create the genomic scaffold. This project opens up new genomic avenues for conifer forestry and breeding, and will act as the base for significant additional studies in the future.
For a full copy of the peer-reviewed article, please visit: http://www.nature.com/nature/journal/vaop/ncurrent/full/nature12211.html
May 1, 2013 – Lucigen Corporation and Research Corporation Technologies (RCT) today announced a partnership to commercialize and distribute the ClearColi™ Expression System, the first Escherichia coli (E. coli)-based recombinant system that lacks unwanted endotoxin. Lucigen will produce and sell kits containing ClearColi™ competent cells and provide contract research services for the ClearColi™ Expression System. Lucigen simultaneously announces the release of a ClearColi™ competent cell line enabling the production of proteins virtually free of endotoxin contamination, thereby minimizing purification and allowing faster and more accurate screening of biological targets for drug discovery research. Under the partnership, RCT will be responsible for the ClearColi™ commercial licensing programs.
Drug discovery researchers are increasingly turning to biologics as the source for new therapeutics, utilizing the incredible diversity of proteins in order to find new treatments for disease. To synthesize and manipulate these proteins, researchers normally insert genes coding for the desired protein into mammalian, yeast, or bacterial cells. The common bacteria E. coli is a widely used system for expression of recombinant proteins, but this method has the disadvantage that, without time-consuming and expensive cleanup, it produces contaminating endotoxin that kills human cells. Failure to remove endotoxin from the final product can result in false or misleading results, potentially causing a researcher to improperly reject a promising drug candidate.
Lucigen and RCT have developed the ClearColi™ competent cell strain for protein expression. This new strain has a genetically modified lipopolysaccharide (LPS) that does not cause an endotoxic response in human cells. By producing proteins without contaminating endotoxin, researchers can increase productivity by reducing the time, cost, and loss of product associated with endotoxin removal. More important, cell-based assays can be performed without concern that LPS (endotoxin) contamination could be masking promising results. Researchers can accelerate drug discovery research and ensure the most accurate results possible. Additional cell lines for plasmid production and phage display are also planned for release, creating a complete system for scientists to study a large variety of biologic compounds for therapeutic applications.
“E. coli is commonly used for research scale protein expression but its ease of use has been limited by unwanted endotoxin contamination. These days are hopefully over. RCT and their collaborators have developed technology allowing for the creation of the first viable E.coli strains lacking endotoxin in the membrane. The ClearColi™ cell lines will accelerate how researchers screen novel compounds for drug discovery. By eliminating the source of endotoxin, scientists can increase the number of compounds screened and more accurately pinpoint candidates for further testing. We are proud to work with RCT to introduce this truly novel system to the world,” states David Mead, Ph.D., Lucigen founder and CEO.
“Lucigen is the ideal partner to launch the ClearColi™ Expression System. They have established themselves as the clear market leader for high efficiency competent cells. We are looking forward to working with them and future licensees of the ClearColi™ Expression System to bring this valuable tool to commercial research and recombinant protein production,” said Chad Souvignier, Ph.D., Managing Director at RCT.
May 1-2, 2013 – David Mead presents “NGS Polymerases” on May 1 at the NHGRI Advanced DNA Sequencing Technology Development Meeting.
April 30th, 2013 – Lucigen will present “New Tools for Difficult Expression Problems: Endotoxin-Free Proteins, Biotinylated Proteins, and More” at the Ninth Annual PEGS meeting in Boston. In addition, we will be exhibiting the entire week of the show, April 29 – May 3. Please come visit us at booth #217 and learn about our new ClearColi™ Competent Cells for endotoxin-free protein expression.
April 29th, 2013 – The 29th Annual Clinical Virology Symposium and Annual Meeting of the Pan American Society for Clinical Virology held April 28-May 1, 2013 in Daytona Beach, FL. Posters presented include:
April 22-25th – Lucigen participated in the BIO International Convention in Chicago, April 22-25th as part of a contingent of companies in the WI pavilion, showcasing biotech leaders from throughout the state. Our ClearColi™ technology was featured in the daily news for all attendees, and we presented our drug discovery solutions as part of the Business Forum.
In collaboration with UW-Milwaukee, David Mead, Founder & CEO of Lucigen, presented on fluorescent proteins & their application in drug discovery.
Feb. 5, 2013 – Lucigen Corporation is proud to announce the 15th anniversary of its founding. Founded on Feb. 5, 1998, Lucigen has grown from two centrifuges in Dr. David Mead’s basement to a world-recognized provider of molecular biology tools for cloning, amplification, protein expression, and next generation sequencing applications. Dr. Mead himself is renowned as the inventor of TA-cloning, which has been widely commercialized by Invitrogen and is still used by a large percentage of the molecular biology community.
Over the course of 15 years, Lucigen has established itself as a high quality provider of innovative, cost effective products and genomic services. Its products are distributed globally by over 50 distributors around the world. Recently, the company has upgraded its facilities by doubling its laboratory and manufacturing space and expects to achieve ISO 13485 certification in 2013.
“We are very proud of the progress Lucigen has made over its lifetime, but we are just getting started. Our business continues to grow, even is this era of difficult funding for our customers. Our goal is to develop innovative products for genomic analysis and firmly stake our claim as a leader in the life science market,” states Dr. Mead.
Lucigen exhibited at CHI PepTalk 2013.
Lucigen exhibited at SLAS 2013.
New Tools for High Throughput Drug Discovery and Production: Endotoxin-free Competent Cell Lines and Novel Methods for GPCR Structural Biology by Curtis Knox Monday, January 14, 2013 at 12:30 to 1:45 PM at Osceola 5-6
Lucigen is exhibiting at PAG 2013. Please come see us at booth # 220. In addition to our booth, please come see our presentation and posters:
October 10, 2012 – Lucigen President Jeff Williams is a featured presenter at Focal Point 2012: Capitalizing on Sustainable Technology. The Oct. 10 conference at the University of Wisconsin-Stevens Point will demonstrate how some of the region’s leading businesses are developing and adopting new technologies that are more sustainable and contribute to their bottom line and competitiveness. Industry leaders will describe how their companies are putting ideas into practice right now. Williams will present “Pathway Engineering: A Novel Approach to Renewable Materials” in a morning session that also features Andrew Held of biofuels pioneer Virent Energy Systems.
Innovative use of renewable raw materials, sustainable construction, biofuels, resource efficiency and biocatalysis operations are session topics. Sessions run consecutively rather than concurrently so conference attendees don’t have to miss anything. See all the conference details and register online early for best price »
October 3-5, 2012 – ChengCang Wu, PhD, presents the following poster at Argonne Soil Metagenomics Meeting:
July 2012 – Lucigen’s Vice President of Enzyme Discovery was highlighted in a recent article entitled: “More than human: Microbes are an essential part of our world – and us”. Schoenfeld’s work regarding metagenomic studies of viruses and other organisms living in Yellowstone National Park’s boiling hot springs and the subsequent discoveries he and his colleagues made are discussed. Read More »
July 10, 2012 – Lucigen Corporation announced today that its unique pJAZZ cloning technology has been used to create a malaria gene library for use by academic researchers worldwide.
The Welcome Trust Sanger Institute in Cambridge, UK, has recently released the PlasmoGEM project online. This collection is the world’s first repository for individual genes from the Plasmodium berghei parasite, which causes malaria in rodents and is a widely used model for human malaria. The library was first published in Nature Methods in October of 2011. With the release of the new website, the Sanger Institute is making it easy for malaria researchers around the world to freely access individual clones from the library, which covers >90% of the genes from the organism. The aim of PlasmoGEM is to provide the malaria research community with a freely accessible resource for genome-wide genetic modification. It has the potential to significantly advance scientific knowledge of malaria and accelerate the search for therapies.
The DNA sequences of P. berghei organism and other Plasmodium species have an unusually high AT content which makes them difficult to clone, and has previously made construction of such DNA libraries impossible. Dr. Ronald Godiska invented Lucigen’s patented pJAZZ vector, which is derived from an E. coli phage and was created for the purpose of stably cloning AT rich and other “unclonable” DNA sequences. Through the use of this technology, the Welcome Trust Sanger Institute has been able to manipulate the genetic material of the parasite and thus create tools for researchers to further study the disease.
“A genomic DNA library that covers most P. berghei genes despite their high AT content is an exciting community resource. Even more importantly, it is a starting point for us to generate a free collection of highly efficient genetic modification vectors. We are aiming to make modification vectors for almost every gene in the P. berghei genome. This will greatly increase the speed at which functions for parasite genes can be found and targets for drugs identified”, stated Oliver Billker, Senior Group Leader, who leads the PlasmoGEM project together with Julian Rayner at the Wellcome Trust Sanger Institute.
“Lucigen was originally founded to clone the most challenging genetic material, and the creation of the pJAZZ vector has enabled scientists worldwide to study genes previously untouchable with existing technologies. The PlasmoGEM project is an extremely important step in malaria research, and we congratulate the Sanger Institute Malaria Program on their efforts”, stated David Mead, Ph.D., founder and CEO.
Lucigen has been tabbed to present “New Tools for Functional Analysis of Genes and Metagenomes” at the 9th International Congress on Extremophiles 2012. This meeting will be held on Sept. 10-13, in Sevilla, Spain. Lucigen is a pioneer in creating tools for cloning and expressing challenging genes from trace amounts of material, and this technology will be featured at the meeting as a method for new gene discovery from unculturable bacteria and viruses. Please join us in Sevilla in September.
June 2012 – A full description of Lucigen’s patented PyroPhage® 3173 enzyme, which was discovered from a boiling hot spring in Yellowstone National Park, was published in PLOS ONE in June 2012. “Thermostable DNA Polymerase from a Viral Metagenome Is a Potent RT-PCR Enzyme” discusses the only known single polymerase to simultaneously perform reverse transcription and DNA amplification by PCR. This enzyme also efficiently strand displaces and is the basis for a 30 minute isothermal molecular diagnostic platform under development at Lucigen. Read the full article »
May 23, 2012 – Lucigen Corporation announced today that it has recently been awarded its largest SBIR Phase II grant to date to fund research and development of a point of care diagnostic test for influenza.
The National Institutes of Health has awarded Lucigen a total of $2.8M in a Small Business Innovation Research grant to be used to develop a point of care (POC) diagnostic testing device for influenza A, B, and respiratory syncytial virus (RSV). Respiratory infections have a significant health and economic impact worldwide, and current test products for the diagnosis of respiratory viral infections such as influenza are inadequate for the timely diagnosis needed for successful implementation of antiviral treatment. Unfortunately, a test product that can accurately diagnose common respiratory viruses with high confidence in less than 30 minutes directly at point of need has not yet been developed. This grant will facilitate Lucigen’s development of an innovative device and reagents for the molecular diagnosis of multiple RNA pathogens that will set a new standard for rapid patient care. The combination of novel molecular technologies, simple protocol, and affordable multiplex testing capabilities residing in a single, inexpensive device will enable near point of care diagnostics for a number of serious infectious agents.
The key factor enabling this game changing technology is the development of a novel enzyme that converts RNA to DNA and isothermally amplifies it in minutes. These attributes have allowed the design of a device that does not use any microfluidics, pumps or valves, therefore greatly simplifying construction and significantly reducing the cost of the test. This new technology is ideal for low resource and battlefield settings, and has long term potential as an over the counter device.
“As a pioneer in cloning, enzyme discovery, and metagenomic studies, Lucigen is now set to leverage its previous breakthroughs into real-world healthcare applications. We plan the world’s first nucleic acid-based test for viral infections that is cost-effective and can be safely and easily used directly at the physician’s office, eliminating the need to send the sample off to central testing laboratories. DNA or RNA based tests have repeatedly shown greater sensitivity and specificity over commonly used “rapid” immunochemistry-based testing methods, but have not been simplified to the extent that they can be moved to a POC situation. Our solution has the potential to significantly advance sensitivity and time to results, thus improving patient treatment and outcomes.” stated David Mead, Ph.D., founder and CEO.
April 21-25, 2012- Lucigen presents two posters at Experimental Biology: 2012
April 21, 2012- Lucigen's Saurabh Sen gives talk: "What industry can offer: Tips for putting your foot inside the door," as part of a professional development series: Career options: the bench, the boardroom or in between?
April 16, 2012 - Lucigen Corporation is pleased to announce that it has recently completed its move into a new, state-of-the-art, office/laboratory facility in Middleton, Wisconsin. Over the course of the past two years, Lucigen has experienced rapid growth in revenues and staff. In order to accommodate our evolution, Lucigen embarked on the process of expansion in mid-2011, culminating in the relocation of the company to a nearby facility remodeled specifically to meet the current and future needs of Lucigen. The new space features greater than double the square footage (now 28,000 ft2) of the previous location and was designed to enhance workflow for R&D, manufacturing, and shipping, while meeting increased regulatory requirements.
“Our new lab, production, and office space will enable Lucigen to continue to augment our product offerings and custom manufacturing capabilities, while enhancing our quality control efforts. We intend to achieve ISO 13485 status by late 2012, thereby increasing our opportunity for partnerships with other life science organizations. The new building is critical to obtaining this goal, and we are excited to settle into our new location,” stated David Mead, Ph.D., founder and CEO.
March 6, 2012 - Lucigen Corporation is pleased to announce that it has recently been awarded its largest SBIR Phase II grant to date to fund additional research and development.
The National Institutes of Health has awarded Lucigen a total of $2.5M in a Small Business Innovation Research grant to be used to develop metagenomic DNA libraries that could identify hundreds of new antimicrobial and other anti-infective drug candidates. More than 100,000 Americans die each year due to untreatable microbial infections, most of which are resistant to current antibiotics. A promising source for new antibiotic structures with potentially novel mechanisms of action is found within natural environments, particularly soils, which have the greatest diversity of microbial life. In a previous Phase I grant, Lucigen and Auburn University scientists used metagenomics (the science of cloning DNA from entire microbial communities) to create a DNA library from soil microbes that resulted in 28 new compounds that inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA). This result is 10-100 times more efficient than earlier efforts from other researchers.
In Phase II, Lucigen and its partners on the grant, Auburn University and the University of Mississippi, will create several large metagenomic libraries, which will be screened for antimicrobial activity against four multiple drug resistant pathogens. Lucigen expects to uncover hundreds of novel chemical entities using this approach from which lead candidates with high potency against multiple bacterial pathogens will be evaluated for efficacy using a novel in vivo MRSA assay. These technologies represent an important advancement for the science of antibiotic discovery. Furthermore, the libraries produced from this research are a valuable genomic resource that may be screened for other bioactive compounds (e.g., anticancer, antifungal, or antiviral activities). The research enabled by this grant will facilitate the creation of a high efficiency drug discovery platform with the potential to uncover thousands of new medicinal compounds.
“One of the ‘Holy Grails’ of functional metagenomics is the ideal of cloning entire small molecule pathways from soil microbes in an effort to discover new antimicrobial compounds from unculturable organisms. Due to technical limitations, prior metagenomic libraries contained gene clusters no more than ~ 40 Kb in length, which is too small to capture the vast majority of small molecule pathways. Lucigen has broken the metagenomic cloning barrier by constructing 100 kb plus gene libraries, with the potential to fully unleash the large diversity of new compounds that exist in nature. With collaborators from Auburn University and the University of Mississippi, the firm hopes to discover new treatments for antibiotic resistant pathogens such as Staphylococcus aureus, as well as develop an entirely new paradigm for drug discovery.” stated David Mead, Ph.D., founder and CEO.
March 7, 2012 - Lucigen has been invited to be a featured speaker at the X-Gen Congress and Expo in San Diego. David Mead, CEO and Founder of Lucigen, will present as part of an instructional course titled “The Key to Quality: Sample Preparation”. There, Dr. Mead will examine the inherent inefficiencies in current methods for next generation sequencing library preparation, including poor DNA fragment A-tailing and ligation, followed by a discussion of improvements to the procedure. These improvements have been incorporated in to Lucigen’s NxSeq™ DNA Sample Prep Kits for next generation sequencing, which are due to be released in Spring, 2012.
February 15-18, 2012 - Posters demonstrating how to make your libraries for NexGen Sequencing more efficient!
Long-Span, Mate-Pair NGS Libraries (PDF) Cheng-Cang Wu, Rosa Ye, Svetlana Jasinovica, Megan Wagner, Amy Hin-Yan Tong*, Si Lok*, Ronald Godiska, Michael J. Lodes, and David Mead Lucigen Corporation, Middleton, WI 53562 *Genome Research Centre, Li Ka Shing Faculty of Medicine, The University of Hong Kong NxSeq™ Technology: Novel Chimera-Free, High Efficiency Library Preparation for NGS Platforms (PDF) Michael J. Lodes, Cheng-Cang Wu, Svetlana Jasinovica, Curtis Knox and David Mead Lucigen Corporation, Middleton, WI 53562
Taq98™ Hot Start 2X PCR Master Mix: 98°C Thermal Denaturation Facilitates Amplification of Difficult Templates (PDF) Michael Moser, Thomas Schoenfeld, Nicholas Hermersmann, Jeff Williams, Krishne Gowda, David Mead Lucigen Corporation, Middleton, WI 53562
January 30, 2012 - Congratulations to Ricelle Acob, Ph.D., of Kuehnle AgroSystems in Honolulu, HI. She successfully found the six mystery words hidden at the beginning of each chapter in our 2011-2012 catalog and won a brand new 16GB iPod Nano.
Dr. Acob's work at Kuehnle Agro Systems revolves around the genetic modification of algae for increased performance and reduced associated costs for renewable biofuels, hydrocarbon chemicals, and nutritional oils and proteins; compatibility with grow-out and process technology. Lucigen congratulates Dr. Acob on her work and on winning the 2nd iPod Nano from our catalog contest.
Jan. 24, 2012 - Lucigen has been awarded a $187,000 grant from the Michael J. Fox Foundation for Parkinson’s Research for the study of LRRK2, a protein found throughout the brain. Excessive activity of LRRK2 has been shown to be associated with Parkinson’s disease (PD). For this reason, many PD researchers are interested in the response of LRRK2 to a variety of compounds. Small chemical compounds that inhibit this enzyme may be helpful in understanding the mechanics of the disease. More importantly, these compounds may lead to drugs that provide effective treatments for PD. The goal of the current grant is to develop a sensitive, high-throughput, inexpensive method to screen thousands of compounds for the inhibition of LRRK2.
“This grant enables Lucigen to utilize our core strengths in protein engineering, along with a proprietary fluorescent protein previously isolated by Lucigen,in order to advance medical research into a devastating disease. As our population ages, we will only see more cases of Parkinson’s. We are proud to join the Michael J. Fox Foundation in the fight against this disease,” states David Mead, CEO.
As part of this grant, Lucigen has added several new research positions at the Company.
January 14-18, 2012 - Workshop: Novel Genome and Proteome Analysis Tools on Tuesday Jan 17, 1:30-3:40 PM, Pacific Salon 1.
pNGS-FOS Long-span Mate-pair Libraries and Chimera-Free NxSeq™ Libraries Random Shear BAC Library Technology Cheng-Cang Wu, Lucigen Corporation Expressionering™ Technology: A New Paradigm for Protein Expression in E. coli and Mammalian Cells. Curtis Knox, Lucigen Corporation
Fosmid pool sequencing of the 20 Gbp genome of Norway spruce (Picea abies) Björn Nystedt, SciLifeLab, Sweden and The Spruce genome project
New Molecular Tools for Long-Span, Mate-Pair NGS Libraries (PDF) Cheng-Cang Wu, Rosa Ye, Svetlana Jasinovica, Megan Wagner, Amy Hin-Yan Tong*, Si Lok*, Ronald Godiska, Michael J. Lodes, and David Mead Lucigen Corporation, Middleton, WI 53562 *Genome Research Centre, Li Ka Shing Faculty of Medicine, The University of Hong Kong Novel Chimera-Free, High Efficiency Library Preparation for NGS Platforms-NxSeq™ Technology (PDF) Curtis Knox, Michael J. Lodes, Cheng-Cang Wu, Svetlana Jasinovica, and David Mead Lucigen Corporation, Middleton, WI 53562
January 2012 Lucigen is pleased to announce two new product lines to its portfolio:
Nov. 30, 2011 Lucigen invites you to view a webinar on our soon to be released NxSeq™ Technology, the next step forward in high-efficiency, chimera-free library preparation for Next Gen Sequencing applications. Find out how you simplify your workflow and get better results for all your NGS projects.
Oct. 12, 2011 Lucigen Corporation is pleased to announce that it has recently been awarded two separate SBIR Phase I grants to fund additional research and development.
The National Institutes of Health has awarded Lucigen a total of $350,000 in Small Business Innovation Research grants to be used to develop research tools with the potential to improve human health. The first grant provides funding for the development of improved tools for “RNA-Seq” techniques used in next generation sequencing applications. RNA-Seq methods are employed in order to study gene regulation and expression; however, current methods suffer from poor accuracy and inherent bias. Lucigen’s portfolio of high-fidelity reverse-transcriptase polymerases, along with the company’s experience in constructing low-bias DNA libraries, will be utilized to create new methods for accurate RNA-Seq applications. The result will enable scientists to gain clearer understanding of gene regulation and subsequently apply this to human health.
The second grant provides funds for the development of an affordable, simple tool for correlating genomic and proteomic data from individual cells using droplet based microfluidic technology. Working in partnership with Auburn University, Lucigen will use this system to develop powerful new enzymes for amplifying very large DNAs. This work will enable researchers to better understand the interaction of cells, proteins and genes in normal and disease situations.
“These grants will enable Lucigen to leverage its core strengths in cloning and genomic research in order to empower genetic researchers worldwide. Scientists will be able to increase their rate of discovery and advance their knowledge of how genes affect health, stated David Mead, Ph.D., founder and CEO.
September 19, 2011 Lucigen Corporation is pleased to announce the release of Taq98™ Hot Start 2X Master Mix. This new DNA polymerase represents a significant step forward in the continuing expansion of product offerings for the company. As part of their mission to simplify genomic research, Lucigen has developed the new Taq98™ Hot Start 2X Master Mix for customers seeking to amplify difficult DNA templates, including targets with >70% GC content. The product combines Taq polymerase with a unique fusion protein that enhances DNA binding, as well as CleanAmp™ dNTP’s from TriLink BioTechnologies. The end result is a highly robust polymerase in an easy-to-use master mix format that avoids primer-dimers and other common PCR problems. More importantly, Taq98™ polymerase has proven its strong ability to amplify numerous “tough template” DNA sequences that fail when amplified with competing products.
“We believe Taq98™ represents a great combination of performance, ease-of-use, and value for the customer. The addition of a hot start master mix to our portfolio has significantly increased our potential reach in the PCR market,” stated David Mead, Ph.D., founder and CEO.
David Mead, Lucigen Corporation, United States New Tools for Functional Analysis of Genes and Meta/Genomes. [pdf of poster] Thermophilic Cellulolytic Enzymes [pdf of poster]
Thomas Schoenfeld, Lucigen Corporation, United States Gene structure, function and diversity of replicase operons assembled from hot springs viral metagenomes. [pdf of poster]
July 18, 2011 As part of Lucigen's continuing effort to educate researchers, we are proud to announce the introduction of a new video channel on YouTube. This site will be a valuable source for product animations, presentations, and instructional talks from Lucigen R&D scientists. The first video housed on the channel is the new Expressioneering™ Technology animation, which explains the inner workings of Lucigen's Expresso® Cloning and Expression kits.
Please visit LucigenVideo regularly to see the newest video uploads to the site.
July 1, 2011 Congratulations to Frances Hannan, Ph.D., of the New York Medical College in Valhalla, NY. She successfully found the six mystery words hidden at the beginning of each chapter in our new 2011-2012 catalog and won a brand new 16GB iPod Nano.
Dr. Hannan studies the molecular mechanisms underlying complex processes such as learning & memory and auditory function. Her team utilizes molecular biology, genetics, and imaging to study nervous system function in the fruit fly Drosophila melanogaster. The main focus of the lab is a Drosophila model for Neurofibromatosis Type I (NFI). This common human genetic disorder causes peripheral nervous system tumors and learning disabilities.
Lucigen applauds the work Dr. Hannan is performing. If you want to enter the catalog contest too, you still have time. Another winner will be announced in January, 2012. Find out more »
July 2011 Lucigen’s Saurabh Sen was recently featured in the American Society for Biochemistry and Molecular Biology’s ASBMB Today Career Insights column. Sen’s interview, titled “Key to Success: Believe in Yourself” provides useful insights in to the world of a post-doc as they move from the academic realm in to a corporate one.
June 21, 2011 Andrew Hollenbach and his team at the LSU Medical Center describe a new method for discovering genomic regulatory elements. His technique, called in vitro PORE (Pull Out Regulatory Elements), enables scientists to rapidly identify novel regulatory elements not discoverable with current ChIP (chromatin immunoprecipitation) methods. In addition, in vitro PORE does not require expensive microarray instrumentation and its associated limitations. Dr. Hollenbach illustrates how his method can be performed quickly and cost effectively using Lucigen products. Download PDF
June 15, 2011 Lucigen presented “Next-Generation Functional and Structural Soil Metagenomics” at the First International Earth Microbiome Project Conference in Shenzhen, China. Dr. Cheng-Cang Wu, Vice President of Genome Technology Development, has been invited by the organizer and BGI (formerly known as Beijing Genomics Institute) to present Lucigen’s innovative work in the areas of metagenomics and the applications of random shear BAC library and next-generation sequencing (NGS) BAC-fosmid libraries. The EMP conference will gather scientists from around the world to discuss ongoing research in microbial ecology as part of the Earth Microbiome Project. This project represents a revolutionary new method for tackling the challenge of microbial ecology and defines both questions and potential suites of tools to provide answers for the future.
June 1-3, 2011
May 9-13, 2011 - Lucigen presented the following poster:
May 8-11, 2011 - Lucigen presented the following poster:
March 21, 2011 - Lucigen Corporation is pleased to announce that it has recently been awarded a SBIR Phase I grant to fund additional research and development.
The National Institutes of Health has awarded Lucigen $226,401 as a Small Business Innovation Research grant to be used to develop research tools with the potential to improve human health. The grant includes funding for the development of improved genomic tools that will subsequently enable discovery and characterization of new therapeutic agents from fungi. Specifically, scientists from Lucigen, in partnership with researchers at the University of Wisconsin-Madison, will identify potential antibiotic compounds from the Aspergillus genus of fungi. Development of antibiotics has reached a significant level of activity not seen since the 1940's as more and more bacteria become resistant to the currently available drugs. This grant will enable discovery of numerous new biological compounds previously unknown to science and has the potential to establish a library of novel small molecules that can be studied for a variety of therapeutic applications in the future.
"This grant will enable Lucigen to leverage its core strengths in cloning and genomic research in order to uncover new compounds with the potential for significant impact on human infectious disease," according to David Mead, Ph.D., founder and CEO.
February 23-25, 2011 - Lucigen presented the following poster:
February 16, 2011 - Lucigen Corporation is pleased to announce that it has recently been awarded a Phase II SBIR grant to fund additional research and development. The National Science Foundation has awarded Lucigen $500,000 as a Small Business Innovation Research grant to be used over the next 2 years to develop tools to improve the health of fish raised by aquaculture. Lucigen has partnered with Auburn University to develop effective and inexpensive methods of detecting and controlling Edwardsiella ictaluri, the most common pathogen in farmed catfish. Infection with this pathogen leads to substantial economic losses for farmers. The goal of this research is to develop rapid tests and natural control agents that will limit the spread of disease without the use of antibiotics or other chemicals. This technology should be applicable to a wide range of agricultural diseases.
“Aquaculture is an increasingly important food source and a vital industry in the US and worldwide. We think the technology we are developing with our collaborators at Auburn has potential to make a significant impact for this industry,” according to David Mead, Ph.D., founder and CEO.
February 2011 - Lucigen presented the following posters at AGBT:
January 17, 2011 - Lucigen Corporation is pleased to announce that it has recently been awarded a Phase II SBIR grant to fund additional research and development. The National Institutes of Health has awarded Lucigen $1,461,160 as a Small Business Innovation Research grant to be used over the next 3 years to develop research tools with the potential to improve human health. The grant includes funding for the development of methods for improved production and subsequent characterization of certain human G-protein coupled receptors (GPCR's). These receptors are found on the surface of most cells and are the target of approximately 40% of drugs on the market today. This important family of proteins holds particular significance for mental health and addiction-related diseases. This grant will be used to develop products that will allow medical researchers to expand their knowledge of this crucial class of drug targets.
"We are pleased to receive this additional funding to further our research. This grant will provide Lucigen with the resources to advance our work on new products to support basic and applied medical research, and will bring several new jobs to the Madison-area." according to David Mead, Ph.D., founder and CEO.
January 2011 - On Tuesday, January 18th, Lucigen presented a workshop entitled "Enabling Discovery Research by Random Shear BAC Libraries" at the Plant and Animal Genome conference in San Diego, CA. BAC libraries, particularly those created by random shear techniques, are key resources for genomics research. As part of the workshop, technology will be highlighted that enables discoveries in crop/plant pathogens and insect or bacterial symbionts as well as drug and industry enzyme discoveries from soil metagenomics. A full workshop agenda can be found below:
Enabling Discovery Research by Random Shear BAC Libraries and New Genome Analysis Tools Speakers:
Sequencing and analyses of the Fusarium viguliforme genome Madan K. Bhattacharyya PhD, Department of Agronomy, Iowa State University Rapidly Identifying the Entire Symbiotic Genome of Candidatus Liberibacter psyllaurous from Psyllid Metagenome BAC Libraries Keremane Manjunath PhD, National Clonal Germplasm Repository for Citrus and Dates, USDA-ARS First-ever Large-insert Random Shear Shuttle BAC Libraries of Soil Metagenomes for Drug and Industrial Enzyme Discovery Cheng-Cang Wu PhD, Lucigen Corporation A New Paradigm for Protein Expression and Functional Genomics in E. coli David Mead PhD, Lucigen Corporation De Novo Sequencing Strategy for Daunting Genomes David Mead PhD, Lucigen Corporation
In addition, Lucigen presented two scientific posters at the conference:
Learn about our newest products and service offerings now including NextGen Sequencing for your microbial, viral, or metagenomic libraries.
September 29, 2010 - Lucigen Corporation is pleased to announce that it has recently been awarded two new grants to fund additional research and development. The National Institutes of Health has awarded Lucigen $301,272 in Small Business Innovation Research grants to be used over the next year to develop research tools with potential to improve human health. The grants include funding for developing methods for generating complete DNA sequences from very large genomes and the creation of DNA libraries from soil microbes for discovery of new antibiotics. The methods developed in these projects will expand and improve applications of Next-Generation Sequencing—an increasingly important technique in personalized medicine and human diagnostics. These grants will be used to support researchers and enable Lucigen to leverage their expertise in the Genomics field. "We are pleased to receive this additional funding to support our research. These grants will provide Lucigen with the resources we need to rapidly advance our work on new products to support basic and applied medical research" according to David Mead, Ph.D., founder and CEO.
May 13, 2010 - Governor Jim Doyle announced Lucigen will receive a $200,000 low-interest loan to develop a DNA sequencing technology. [Read more from the Journal Sentinel]
| Dr. Ron Godiska of Lucigen and |
Representative Tammy Baldwin.
April 30, 2010 - Congresswoman Tammy Baldwin visited Lucigen to discuss the future of the Small Business Innovation Research (SBIR) Program and to learn first-hand the impact of the SBIR Program on companies like Lucigen. For nearly 20 years, this program has provided grants to small, innovative companies to develop and commercialize novel technologies. Approximately 6000 active SBIR grants provide funding for research that enables the commercial development of thousands of products nationwide, each year. Lucigen has utilized this source of funds to develop novel cloning systems and enzymes, which are being sold to customers around the world. Following a tour of the facility, she spoke with Lucigen’s CEO, President, and numerous employees, gaining knowledge of the SBIR program in action.
Despite the success of the SBIR Program, Congressional efforts are afoot to shift a significant portion of the funding to larger, venture-backed firms. It is important that our Congressional Representatives fully understand the potential impact of this on smaller companies. Representative Baldwin visited Lucigen specifically to discuss the merits of the current SBIR funding structure and the potential impact that any proposed changes might have on Lucigen.
Interested in supporting SBIR? Contact your federal representatives to voice your opinion on the SBIR Program.
April 20, 2010 - Lucigen Corporation is pleased to announce that it has recently been awarded three new grants to fund additional research and development.
The National Institutes of Health has awarded Lucigen $1,764,732 in Small Business Innovation Research grants to be used over two years to develop research tools and diagnostic assays with potential to improve human health. The grants include funding for: 1) development of a simple, sensitive, all-in-one point of care virus-detection system (Phase I award of $400,000), 2) advancement of cloning methods with the goal of identifying novel antibiotics for future clinical development (Phase I award of $164,732), and 3) enhancement of a system for expressing genes which are toxic or unstable in currently available systems (Phase II award of $1,200,000). These three grants will be used to support researchers and enable Lucigen to leverage their expertise in the fields of Genomics and Proteomics.
“We are pleased to receive this additional funding to support our research. These grants will provide Lucigen with the resources we need to rapidly advance our work on new products to support basic and applied medical research, as well as clinical diagnostics” according to David Mead, Ph.D., founder and CEO.
April 2010 - Lucigen is transitioning from high impact, polystyrene (#6 HIPS) boxes that weigh up to 26 grams to recyclable low density polyethylene (#4 LDPE), that weighs less than 1 gram where possible. Resulting in less raw material, less energy used, easier recycling, better for the environment.
|Dr. David Mead and Tom Barrett.|
February 18, 2010 - Milwaukee mayor and Wisconsin gubernatorial candidate Tom Barrett recently toured Lucigen’s facility, re-affirming his support for Wisconsin’s growing biotechnology industry. Barrett spoke with Lucigen’s founder, Dr. David Mead, who highlighted Lucigen’s current and future goals. The Milwaukee Mayor later spoke with other Lucigen scientists to better understand the workings of a biotechnology company. Dr. Cheng-Cang Wu, Vice-President of Custom Services, discussed Lucigen’s unique methods and robotic technology for whole genome cloning. Lynne Sheets, Production Scientist, described her career path at Lucigen beginning as an intern to her current position, where she contributes to product development and product commercialization. Mr. Barrett also discussed Lucigen’s research into thermophilic bacteria and bacteriophage obtained from hot springs with Tom Schoenfeld, Vice-President of Enzyme Discovery.
|Dr. Patrick Burke at PAG.|
January 2010 - Drs. Cheng-Cang Wu and Patrick Burke attended the Plant and Animal Genome XVIII Conference. In addition to exhibiting Lucigen’s products and services, highlights included:
PAG XVIII brought together the leading genetic scientists and researchers involved in plant & animal research and related areas. With over 50 countries represented, the Plant & Animal Genome Conference provided a forum for the global exchange of information. Lucigen is pleased to be able to provide tools to help this important research progress. Learn more about Custom Services including Random Shear BAC Libraries.
December 2009 - Dr. Ronald Godiska of Lucigen, along with several academic collaborators, has published a research article describing the unique pJAZZ® Linear Vector used in Lucigen’s BigEasy® v2.0 Linear Cloning System. This paper demonstrates the utility of the pJAZZ vector for:
“Linear plasmid vector for cloning of repetitive or unstable sequences in Escherichia coli”, is published in Nucleic Acids Research and is available free of charge.
|Dr. Patrick Burke at PEGS.|
October 2009 - Dr. Patrick Burke, Technical Product Manager, represented Lucigen at Cambridge Health Institute’s Protein Expression Summit (PEGS) in Hannover, Germany. This special-topic conference focused on protein expression and antibody development including a full day on Phage Display of Therapeutic Antibodies. Information on all Lucigen’s products was presented with particular focus on competent cells for phage display at the booth and in a poster. Watch SelectScience’s interview regarding Lucigen's featured products.
Dr. Burke also met with Lucigen’s distributors in Germany, BioCat GmbH, and France, Euromedex France. These meetings provided an occasion to share information regarding the needs of European scientists, the solutions offered by current Lucigen products, and feedback for the development of future research tools. The conference and the meetings were invaluable sources of customer feedback and Lucigen is grateful to BioCat and Euromedex for their support.
| Dr. Cheng-Cang presenting on |
Lucigen's enzyme discovery program.
September 2009 - Dr. Cheng-Cang Wu, Vice President of Genome Technology Development at Lucigen Corp. was invited by MingRui Biotech Co., located in Shanghai, China to discuss recent technology advancements. In September 2009, Dr. Wu provided training on Lucigen products and gave a presentation on ‘New enzyme discovery from Yellowstone Hot Springs, unique bacterial linear cloning system, and their applications’ to the local customers, mainly from Chinese Academy of Sciences (CAS). Dr. Wu also met individually to discuss customer questions and listen to their feedback. Lucigen appreciates opportunities to work with distributors, and thanks MingRui Biotech for providing such an opportunity.
September 16, 2009 - Lucigen Corporation is pleased to announce that it has been awarded a new grant to fund additional research and development.
The National Institutes of Health has awarded Lucigen $750,000 to be used over two years to develop enzymes and methods for nucleic acid sequencing. This work may lead to faster and less expensive methods of sequencing DNA, which is important in the emerging field of personalized medicine. Determining a patient’s genetic makeup quickly and inexpensively will help health care professionals better determine the correct drugs with which to treat the patient, resulting in better outcomes. Furthermore, knowing one’s genetic predisposition for disease may help an individual take corrective action before a disease develops.
“We are pleased to receive this additional funding to support our research. This grant will provide Lucigen with the support we need to advance our work to support the rapidly developing field of personalized medicine” according to David Mead, Ph.D., Principle Investigator on the grant, and founder and CEO.
August, 2009 - Lucigen scientists, Tom Schoenfeld and David Mead, hiked into the Heart Lake thermal basin of Yellowstone National Park in August of 2009 to collect microbial samples for research projects associated with the Great Lakes Bioenergy Research Center at University of Wisconsin Madison. The collection trip focused on thermophilic microbes associated with decaying woody biomass, with the goal of improving industrial biofuels production by providing robust enzymes able to function optimally at the high temperatures required for these processes. The team also studied the viruses inhabiting these near-boiling hot springs as part of an investigation into microbial and viral diversity and host defenses in these unique environments. This research has provided enzymes that are key components of DNA and RNA amplification systems.
The research was conducted under permits obtained from the National Parks Service. Unlike other extractive methods, our method of bioprospecting leaves a very small environmental footprint. Our collections are all less than 2 liters taken from an outflow channel, immediately before the water enters the stream, and the hotsprings remain untouched. Montana State University Professors Brent Peyton, Matthew Fields and Robin Gerlach served as guides to the remote area.
Related published articles by Lucigen scientists:
July 7, 2009 - Lucigen Corporation is pleased to announce that it has been awarded a new grant to fund additional research and development.
The National Science Foundation has awarded Lucigen and its collaborators at Auburn University $100,000 to develop methods for molecular diagnostics and biological control of disease in farmed channel catfish. This work may lead to diagnostic kits and other products to help eliminate the spread of disease in farm-raised channel catfish, an important food crop.
“As wild stocks of fish decline, aquaculture is an increasingly important food source for a growing number of people. A major impediment to its development is disease among the farmed fish. This goal of this project is to provide catfish farmers a rapid, affordable means for early detection of their most problematic disease and for treatment with natural antimicrobials. This technology should be applicable to other types of fish, as well,” said Thomas Schoenfeld, Principle Investigator on the grant.
“We are pleased to receive this additional funding to support our research. This grant will provide Lucigen with the support we need to develop products which will help safeguard the production of the channel catfish farming industry,” according to David Mead, Ph.D., founder and CEO.
With these grants, Lucigen has received more than $700,000 in federal grant funding over the past year, and more than $4.2 million in total grant funding.
May 5, 2009 - Lucigen Corporation is pleased to announce that it has been awarded two new grants to fund additional research and development.
The National Science Foundation has awarded Lucigen $100,000 to further develop a nucleic acid replicating enzyme, which was discovered in a sample taken from a boiling-hot spring. The enzyme has several properties that may be useful in cancer diagnosis and infectious disease detection.
Lucigen will also share in an award of $300,000 from the National Institute of Allergy and Infectious Diseases to develop a simple, point of care test for infectious agents. The test is based on technology developed jointly by Lucigen and Dr. Abhay Vats, M.D., at the University of Pittsburgh. The funds will be used to develop tests for respiratory viruses, which can be performed in the doctor’s office or clinic, rather than in a diagnostic laboratory. This work may reduce the cost and improve the delivery of treatment for many respiratory illnesses, such as influenza.
“We are pleased to receive this additional funding to support our research. These grants will provide Lucigen with the support we need to develop several key products, which we feel could have a major impact on the early detection of disease,” according to David Mead, Ph.D., founder and CEO.
With these grants, Lucigen has received more than $600,000 in federal grant funding over the past year, and more than $4.1 million in total grant funding.
April 2, 2009 - Lucigen Corporation is pleased to announce that Jeff Williams has joined the company as its new President. Jeff brings over 20 years of relevant experience, having previously held senior level management positions at leading life science and diagnostic companies. He comes to Lucigen from Platypus Technologies where he was President and CEO. Jeff has also held Vice President positions at Roche Diagnostics, Ambion, and Asuragen where he focused on operations, and product and business development. He holds a B.S. in Biochemistry and a Ph.D. in Pharmaceutical Biochemistry from the University of Wisconsin- Madison.
“Jeff brings a wealth of operations and management expertise to Lucigen. We are fortunate to find someone of his caliber,” according to David Mead, Ph.D., founder and CEO. “We intend to utilize his experience to build the infrastructure and internal processes we will need to keep up with our rapid growth.”
August 2 , 2007 - Lucigen Corporation (Middleton, WI) was awarded a $250,000 grant from the National Institute of Mental Health (NIMH). The grant will fund development of new methods to analyze membrane proteins using the company’s proprietary gene cloning and protein expression technologies. Membrane proteins are highly important targets in developing drugs against many human diseases. However, difficulties in cloning and preparing membrane proteins have slowed research into how they function in normal and diseased cells. Lucigen expects that its new methods will allow much faster analysis of membrane proteins and speed development of new, more effective pharmaceuticals.
June 26, 2007- Lucigen Corporation, in conjunction with its spin-off company C56 Technologies, was chosen by the US Department of Energy (DOE) in a competitive review process to be a commercial participant included in the new national initiative to develop cellulosic-based biofuels. DOE is providing $375 million over 5 years to fund three Bioenergy Research Centers. The funding is part of President Bush's “Twenty in Ten” initiative, which seeks to reduce U.S. gasoline consumption by 20 percent within 10 years through the development of renewable, carbon-neutral energy sources. Lucigen and C5-6 Technologies are included in the Great Lakes Bioenergy Research Center, headed by the University of Wisconsin-Madison. Lucigen and C5-6 Technologies will use the funding to speed discovery, development and commercialization of high efficiency enzymes for biofuel production from low-value cellulosic sources such as agricultural residues, grasses, poplar trees, inedible plants, and non-edible portions of crops. For more information, please click here.
April 19, 2007 - Lucigen Corporation (Middleton, WI) received a Phase II SBIR follow-on grant from the National Institutes of Health to complete development and commercialization of new DNA polymerases for high throughput genomic sequencing. The company discovered these enzymes in previously unknown viruses from boiling hot springs.
Lucigen has been “bioprospecting” hot springs and other high temperature environments by using proprietary methods to clone and screen the genomes of rare bacteria and viruses for novel enzymes. Because of their environment, these microbes have developed enzymes that work most effectively at high temperatures. The company’s first bioprospecting discovery was cellulase and xylanase enzymes that promise to increase yields in bioethanol production from corn, a high temperature process. Last year Lucigen spun off another company, C5-6 Technologies, to commercialize these enzymes. C5-6 is expanding this work in developing enzymes for biofuel production from soybeans and biomass.
The DNA polymerases Lucigen is developing with the NIH grant are the second bioprospecting find. Similar, but less efficient, high temperature enzymes are now used in automated DNA sequencers used in research, molecular diagnostics, and drug discovery. Lucigen is collaborating with two leading manufacturers of automated DNA sequencers to eventually integrate these enzymes with their instrumentation.
March 30, 2006 - Lucigen Corporation (Middleton, WI) received a $750,000 SBIR phase II grant from the National Human Genome Research Institute of the National Institutes of Health. The company will use the funding to commercialize several new technologies that are expected to streamline gene cloning and analysis. Founded in 1998, Lucigen uses its patented and proprietary gene technologies to discover new types of enzymes for biomedical research, diagnostics, pharmaceuticals, and high efficiency ethanol production from corn and biomass for fuels.
November 3, 2005 - Lucigen Corporation (Middleton, WI) received a $400,000 SBIR Phase II grant from the National Institutes of Health to develop a new generation of tools for faster and easier construction of gene "libraries". Gene libraries are widely used in biomedical research, development of molecular diagnostics for genetic diseases, and discovery of new biopharmaceuticals. In addition to commercializing these new tools as products, the company will use them in its own programs to discover and develop novel enzymes expected to offer much better performance and efficiency in research, diagnostics, drug discovery, and industrial processes including ethanol production from corn for fuels.
Lucigen Corporation has been chosen as one of five finalists for the State of Wisconsin Governor's Small Business Technology Transfer Award. The Award, sponsored by the Wisconsin Department of Commerce and the Center for Technology Transfer, recognizes an outstanding Wisconsin small business that has taken a technology innovation to profitable commercialization. Lucigen's nomination for the Award was based on the company's novel CloneSmart® and related ultra high efficiency gene cloning technologies, products, and services.
Lucigen Corporation (Middleton, WI) has received an SBIR grant from the National Institutes of Health to develop a high throughput screening technology for identifying new types of DNA polymerases. These enzymes are widely used in biomedical research, tests for viruses and other pathogens, and diagnostics for genetic-based diseases. Lucigen will use this technology to screen for DNA polymerases in gene libraries prepared from previously inaccessible rare microbes living in boiling hot springs. The company is already developing a series of novel enzymes expected to offer much better performance and efficiency in research, diagnostics, drug discovery, and industrial processes like ethanol production from corn for fuels.
MADISON, Wis. (January 18, 2004) – The Center for Technology Transfer Inc. (CTT) has committed $250,000 in equity funding to Middleton, Wis., based Lucigen Corporation. Lucigen is working on the development of enzymes that can improve the energy efficiency of ethanol production and other similar processes. CTT's investment will be used to fund further development in this area and will also serve as match funding in the event Lucigen obtains federal grants. This investment completes a $1 million private placement by Lucigen.
Lucigen's core expertise and business is discovering, developing and marketing novel enzymes and enzyme-related products of high commercial value. Lucigen invented the ultra efficient DNA cloning technologies (patents pending) that are incorporated into its current CloneSmart™ gene cloning and genomics products, NanoClone™ cloning services, and Single Cell Genomics technology for new product discovery. The company currently sells more than 50 different biomedical research products and services. It has already been awarded $5 million in competitive SBIR grants from the National Institutes of Health, National Science Foundation, and the US Department of Energy in recognition of the commercial value of its technologies and expertise.
Dr. David Mead, Lucigen's founder and CEO, remarked that working with CTT "had been a very efficient process". He added, "We really appreciate the help and support that CTT has provided. There is not nearly enough of this in Wisconsin and it makes a tremendous difference to a small firm like ours. That is one of the reasons we have also invited a CTT representative to join our Board of Directors."
"We are very excited about Lucigen's technology and strong group of backers," said CTT President Masood Akhtar. "We are providing this funding in order to help support this promising area that could lead to considerable energy savings in the production of ethanol, a renewable source of energy."
CTT is a private, non-profit 501(c)3 corporation dedicated to commercializing new energy-saving technologies in Wisconsin. CTT has an investment fund and employs an investment model for technology commercialization. CTT is largely funded by the Wisconsin Department of Administration through its Focus on Energy Program, Wisconsin's energy efficiency and renewable energy initiative. CTT works mainly with early-stage companies, but will consider project financing to bring energy best practices to Wisconsin.
About Lucigen Corporation
Lucigen Corporation was founded in Wisconsin in 1998 by Dr. Mead who has eighteen years of experience in the field.
For more information about:
CTT, call Masood Akhtar 608-661-4081 or 661-4086 or visit www.cttinc.org.
Lucigen, call David Mead 608-831-9011 or visit www.lucigen.com.
For the second year in a row, Lucigen has been chosen to present at the annual Wisconsin Life Sciences & Venture Conference, November 16 & 17 in Madison. Criteria for selection were technology advantage, market opportunity, management team, company strategy, and investor appeal. The selection committee included venture capitalists, business consultants, and individuals with experience in founding and developing technology companies.
Lucigen Corporation and VWR International Inc. have concluded a distribution agreement giving VWR non-exclusive rights to distribute Lucigen products under the Lucigen label in the US and Canada. VWR, a leading supplier of research products to the global life sciences market, has worldwide sales of more than $2.5 billion.
Lucigen Corporation (Middleton, WI) was notified that on Monday, September 20, 2004, a distinguished panel of microbiologists convened by the US Department of Energy reviewed more than 65 nominations in projects to address DOE's needs in the areas of bioremediation, carbon sequestration, and biofuels production. Lucigen received one of the highest priority awards in proposing use of the company's novel DNA cloning technologies to investigate rare, previously unknown microbial life forms in boiling hot springs. Lucigen will develop gene libraries from these rare microbes which will then be sequenced by DOE's Joint Genome Institute in Walnut Creek, CA. Lucigen will analyze the DNA sequence data to identify and commercialize high value biological products. Total value of the award in sequencing services for Lucigen is estimated to be $1 million. The company is developing new enzymes for biomedical research, diagnostics, drug discovery, and industrial processes including low cost bioethanol production from corn for fuel use.
Lucigen Corporation (Middleton, WI) received the maximum $250,000 awarded from the National Science Foundation under a special SBIR grant program to commercialize new products and technologies with high potential value. Under this program, NSF matched a percentage of the funds raised by Lucigen from outside investors. The award will speed commercialization of novel enzymes from rare microbes discovered using Lucigen's proprietary Single Cell Genomics technology.
Lucigen has been awarded US Pat. No. 6,709,861 "Cloning Vectors and Vector Components" covering key elements of Lucigen's transcription-free, ultra high efficiency vectors for cloning deleterious sequences, multiplex cloning, multiplex sequencing, and fixed orientation cloning. Additional patents are pending. Licenses to the CloneSmart Technology and vectors are available for selected applications and fields-of-use. Contact Lucigen for details.
Lucigen has been chosen to give a presentation on the company, its products and technologies at the Wisconsin Life Sciences Venture Conference 2003, to be held November 4-5 at the Monona Terrace Convention Center, Madison, WI. The company is seeking additional equity financing to commercialize its Single Cell Genomics technology for new product discovery, and to expand its R&D, manufacturing, marketing, and business operations.
Lucigen Corporation, a Middleton Wisconsin biotechnology company, has received one of only four in-kind DNA sequencing grants awarded in national competition by the US Department of Energy (DOE) through its Genomes to Life Program.
DOE's Joint Genome Institute will perform 100,000,000 sequence reads of DNA provided by Lucigen from rare, previously unknown microbes accessible only with the company's proprietary Single Cell Genomics technology. This DNA sequencing is expected to identify genes for new kinds of enzymes and other proteins with potential applications in biomedical research, diagnostics, drug discovery, and industrial processing.
Lucigen will have exclusive use of this DNA sequence information for 6 months, after which it will be publicly available in the GenBank data base.
Lucigen Corporation, a Middleton Wisconsin biotechnology company, has been awarded a $750,000 Phase II SBIR grant from the US Department of Energy (DOE). The grant, funded through the DOE's Genomes to Life Program, was awarded in recognition of the scientific merit and high commercial potential of Lucigen's Single Cell Genomics gene mining technology. This technology for the first time allows the isolation and cloning of genes from a single cell or virus. In contrast, current gene cloning methods are a billion-fold less efficient, requiring that a cell or virus sample first be cultured, or grown in the laboratory, to generate the large number of cells needed. Because 99% of the cells or viruses in the environment cannot be cultured, Single Cell Genomics is expected to open up entirely new sources of products for biomedical research, diagnostics, pharmaceuticals, agriculture, and industrial processing. Lucigen, founded in 1998, is a privately held company manufacturing and selling products worldwide for gene cloning and genomics.
Lucigen Corporation, a Middleton Wisconsin biotechnology company, has been awarded four concomitant SBIR phase I and II grants totaling $800,000 from the National Institutes of Health, National Science Foundation, National Human Genome Research Institute and the Department of Energy. The funding will be used to develop a suite of related molecular tools for genome research and will enhance Lucigen's genomic analysis and discovery platforms. Lucigen, founded in 1998, is a privately held company that manufactures and sells products for biomedical research.
Lucigen Corporation announced that it has signed distribution agreements with representatives in Australia, Austria, Belgium, Brazil, France, Germany, Ireland, Japan, Korea, Netherlands, Switzerland, Taiwan and the United Kingdom. These relationships will allow us to better serve our global customers.
Lucigen Corporation announced that it has received the second year of funding for a Phase II SBIR award from the National Human Genome Research Institute, National Institutes of Health, to continue developing its multiplex cloning and sequencing technologies. These technologies are directly applicable to the worldwide efforts to decipher the genetic codes of humans, mice, rats, cattle, maize, plasmodium, various microbes and other organisms.
Going to Extremes
by Nicole Miller published in Grow Magazine, from UW-Madison’s College of Agricultural and Life Sciences.
State Firm On The Trail Of Tiny Critters In Yellowstone's Steamy Pools
by Judy Newman, published in the Wisconsin State Journal, April 9, 2006, used with permission.
One cell, big potential - Middleton's Lucigen helps scientists unravel DNA
by Jeff Richgels, published in The Capitol Times, October 23, 2003, used with permission.